Creating a paradigm shift in raw materials
Synthetic biology based on natural genomic knowledge has wide-ranging potential to advance how we bring more effective and safer therapeutics to patients. It allows us to treat more patients by speeding production and lowering cost.
Synthetic DNA does not require larger fermentation volumes of plasmids. This means we can generate DNA with no bacterial impact that can be produced in higher volumes in significantly less time than plasmid DNA. More importantly, we can assemble safer DNA sequences at a larger scale with the same therapeutic effect of natural synthesized DNA.
Working collaboratively with TAAV Biomanufacturing Solutions, AskBio is advancing Doggybone™ DNA (dbDNA™)* into clinical applications with extensive development and manufacturing capabilities.
*Touchlight™, proTL™, dbDNA™, doggybone™and doggyboneDNA™ are all trademarks of Touchlight Genetics Limited.
We believe that dbDNA™ will provide a better, safer, faster and more scalable DNA solution than currently on the market. dbDNA closed-linear constructs are known as doggybones due to their schematic structure.
- Novel, minimal linear double-stranded DNA vector
- Closed ends improve expression characteristics
- Capable of long and difficult sequences
- Eliminates bacterial sequences
Doggybone™ DNA for better AAV therapeutics
TAAV’s process for producing dbDNA™
“Doggybone™ DNA is best-in-class synthetic technology that will revolutionize our AAV platform and will play an important role in the future of genetic medicine.”
Philippe Moullier, MD, PhD
Chief Scientific Officer, Europe